ICIs single drug or combination with chemotherapy has been recommended for second-line treatment of advanced NSCLC and first-line treatment of advanced NSCLC with positive PD-1/PD-L1 expression (≥50%) and no EGFR, ALK-driven gene mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.